Clinical Trial Update: A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of an adjuvanted tuberculosis subunit vaccine in PPD-positive volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Adjuvanted tuberculosis subunit vaccine

Snippet

Sponsor: Statens Serum Institut | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED